Eagle Asset Management Inc Seagen Inc. Transaction History

Eagle Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$127.59 - $203.08 $55,756 - $88,745	-437 Reduced 0.08%	525,787 $106 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $95,421 - $113,145	813 Added 0.15%	526,224 $67.6 Million
Q3 2022 Nov 07, 2022	BUY	$135.27 - $180.11 $321,401 - $427,941	2,376 Added 0.45%	525,411 $71.9 Million
Q2 2022 Aug 10, 2022	BUY	$108.81 - $179.33 $1.31 Million - $2.15 Million	11,997 Added 2.35%	523,035 $92.5 Million
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $301,417 - $397,782	2,520 Added 0.5%	511,038 $73.6 Million

Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $437,262 - $585,367	3,067 Added 0.61%	508,518 $79.9 Million
Q3 2021 Nov 10, 2021	SELL	$142.45 - $169.82 $4.58 Million - $5.46 Million	-32,162 Reduced 5.98%	505,451 $85.8 Million
Q2 2021 Aug 11, 2021	SELL	$135.08 - $161.1 $39,308 - $46,880	-291 Reduced 0.05%	537,613 $84.9 Million
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $3.72 Million - $5.16 Million	27,025 Added 5.29%	537,904 $77.1 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $84.1 Million - $108 Million	510,879 New	510,879 $89.5 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.